International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 38

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996.*

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMENDÉES (DCI Rec): Liste 38

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996.*

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 38

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996.*

MODIFICATION

This is to inform you that WHO will henceforth publish lists of recommended INNs **twice a year.**

This new measure is intended to provide information as soon as possible on the names that have reached the status of recommended INNs.

MODIFICATION

L'OMS publiera désormais les listes des DCI recommandées **deux fois par an.**

Cette nouvelle mesure est destinée à informer les lecteurs dès que possible au sujet des dénominations ayant atteint le statut de DCI recommandée.

MODIFICACION

De ahora en adelante, la OMS publicará **dos veces por año** las listas de DCI recomendadas.

Con esta nueva medida se quiere facilitar lo antes posible la información sobre las denominaciones a las que se ha asignado la condición de DCI recomendadas.

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada*

abacavirum

abacavir	(1*S*,4*R*)-4-[2-amino-6-(cyclopropylamino)-9*H*-purin-9-yl]-2-cyclopentene-1-methanol
abacavir	[(1*S*,4*R*)-4-[2-amino-6-(cyclopropylamino)-9*H*-purin-9-yl]cyclopent-2-énylméthanol
abacavir	(1*S*,4*R*)-4-[2-amino-6-(ciclopropilamino)-9*H*-purin-9-il]-2-ciclopenteno-1-metanol
	$C_{14}H_{18}N_6O$



almotriptanum

almotriptan	1-[[[3-[2-(dimethylamino)ethyl]indol-5-yl]methyl]sulfonyl]pyrrolidine
almotriptan	1-[[[3-[2-(diméthylamino)éthyl]-1*H*-indol-5-yl]méthyl]sulfonyl]pyrrolidine
almotriptán	1-[[[3-[2-(dimetilamino)etil]indol-5-il]metil]sulfonil]pirrolidina
	$C_{17}H_{25}N_3O_2S$



amlintidum

amlintide

L-lysyl-L-cysteinyl-L-asparaginyl-L-threonyl-L-alanyl-L-threonyl-L-cysteinyl-L-alanyl-L-threonyl-L-glutaminyl-L-arginyl-L-leucyl-L-alanyl-L-asparaginyl-L-phenylalanyl-L-leucyl-L-valyl-L-histidyl-L-seryl-L-seryl-L-asparaginyl-L-asparaginyl-L-phenylalanylglycyl-L-alanyl-L-isoleucyl-L-leucyl-L-seryl-L-seryl-L-threonyl-L-asparaginyl-L-valylglycyl-L-seryl-L-asparaginyl-L-threonyl-L-tyrosinamide, cyclic(2→7)-disulfide

amlintide

(2→7)-disufure cyclique de L-lysyl-L-cystéinyl-L-asparaginyl-L-thréonyl-L-alanyl-L-thréonyl-L-cystéinyl-L-alanyl-L-thréonyl-L-glutaminyl-L-arginyl-L-leucyl-L-alanyl-L-asparaginyl-L-phénylalanyl-L-leucyl-L-valyl-L-histidyl-L-séryl-L-séryl-L-asparaginyl-L-asparaginyl-L-phénylalanyl-glycyl-L-alanyl-L-isoleucyl-L-leucyl-L-séryl-L-séryl-L-thréonyl-L-asparaginyl-L-valyl-glycyl-L-séryl-L-asparaginyl-L-thréonyl-L-tyrosinamide

amlintida

(2→7)-disulfuro cíclico de L-lisil-L-cisteinil-L-asparaginil-L-treonil-L-alanil-L-treonil-L-cisteinil-L-alanil-L-treonil-L-glutaminil-L-arginil-L-leucil-L-alanil-L-asparaginil-L-fenilalanil-L-leucil-L-valil-L-histidil-L-seril-L-seril-L-asparaginil-L-asparaginil-L-fenilalanilglicil-L-alanil-L-isoleucil-L-leucil-L-seril-L-seril-L-treonil-L-asparaginil-L-valilglicil-L-seril-L-asparaginil-L-treonil-L-tirosinamida

$C_{165}H_{261}N_{51}O_{55}S_2$



avitriptanum

avitriptan

3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-*N*-methylindole-5-methanesulfonamide

avitriptan

[3-[3-[4-(5-méthoxypyrimidin-4-yl)pipérazin-1-yl]propyl]-1*H*-indol-5-yl]-*N*-méthylméthanesulfonamide

avitriptán

3-[3-[4-(5-metoxi-4-pirimidinil)-1-piperazinil]propil]-*N*-metilindol-5-metanosulfonamida

$C_{22}H_{30}N_6O_3S$



bamaquimastum

bamaquimast — 3-(3-hydroxypropyl)-1-propyl-2(1*H*)-quinoxalinone methylcarbamate (ester)

bamaquimast — méthylcarbamate de 3-(3-oxo-4-propyl-3,4-dihydroquinoxalin-2-yl)propyle

bamaquimast — metilcarbamato(éster) de 3-(3-hidroxipropil)-1-propil-2(1*H*)-quinoxalinona

$C_{16}H_{21}N_3O_3$



basiliximabum

basiliximab — immunoglobulin G 1 (human-mouse monoclonal CHI621 heavy chain anti-human interleukin 2 receptor), disulfide with human-mouse monoclonal CHI621 light chain, dimer

basiliximab — immunoglobuline G 1 (chaîne lourde de l'anticorps monoclonal chimérique homme-souris CHI621 dirigé contre le récepteur humain de l'interleukine 2), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal chimérique homme-souris CHI621

basiliximab — inmunoglobulina G 1 (cadena pesada del anticuerpo monoclonal quimérico hombre-ratón CHI621 dirigido contra el receptor humano de la interleuquina 2), dimero del disulfuro con la cadena ligera del anticuerpo monoclonal quimérico hombre-ratón CHI621

betadexum

betadex — β-cyclodextrin

bétadex — β-cyclodextrine

betadex — β-ciclodextrina

$C_{42}H_{70}O_{35}$



bimoclomolum

bimoclomol (±)-*N*-(2-hydroxy-3-piperidinopropoxy)nicotinimidoyl chloride

bimoclomol chlorure de *N*-[(2*RS*)-2-hydroxy-3-(pipéridin-1-yl)propoxy]pyridin-3-carboximidoyle

bimoclomol cloruro de (±)-*N*-(2-hidroxi-3-piperidinopropoxi)nicotinimidoil

$C_{14}H_{20}ClN_3O_2$



and enantiomer
et l'énantiomère
y enantiómero

blonanserinum

blonanserin 2-(4-ethyl-1-piperazinyl)-4-(*p*-fluorophenyl)-5,6,7,8,9,10-hexahydrocyclo=octa[*b*]pyridine

blonansérine 2-(4-éthylpipérazin-1-yl)-4-(4-fluorophényl)-5,6,7,8,9,10-hexahydrocyclo=octa[*b*]pyridine

blonanserina 2-(4-etil-1-piperazinil)-4-(*p*-fluorofenil)-5,6,7,8,9,10-hexahidrociclo=octa[*b*]piridina

$C_{23}H_{30}FN_3$



brasofensinum

brasofensine 3β-(3,4-dichlorophenyl)-1α$_H$,5α$_H$-tropane-2α-carboxaldehyde (*E*)-(*O*-methyloxime)

brasofensine (1*R*,2*R*,3*S*,5*S*)-3-(3,4-dichlorophényl)-8-méthyl-8-azabicyclo[3.2.1]octane-2-carbaldéhyde (*E*)-*O*-méthyloxime

brasofensina 3β-(3,4-diclorofenil)-1α$_H$,5α$_H$-tropano-2α-carboxaldehído (*E*)-(*O*-metiloxima)

$C_{16}H_{20}Cl_2N_2O$



brinzolamidum

brinzolamide (*R*)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2*H*-thieno[3,2-*e*]-1,2-thiazine-6-sulfonamide 1,1-dioxide

brinzolamide (4*R*)-4-(éthylamino)-2-(3-méthoxypropyl)-3,4-dihydro-2*H*-thiéno[3,2-*e*]-1,2-thiazine-6-sulfonamide 1,1-dioxyde

brinzolamida (*R*)-4-(etilamino)-3,4-dihidro-2-(3-metoxipropil)-2*H*-tieno[3,2-*e*]-1,2-tiazina-6-sulfonamida 1,1-dióxido

$C_{12}H_{21}N_3O_5S_3$



cevimelinum

cevimeline (±)-*cis*-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine]

céviméline (3*RS*,2'*RS*)-2'-méthylspiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane]

cevimelina (±)-*cis*-2-metilespiro[1,3-oxatiolano-5,3'-quinuclidina]

$C_{10}H_{17}NOS$



and enantiomer
et l'énantiomère
y enantiómero

cizolirtinum

cizolirtine (±)-5-[α-[2-(dimethylamino)ethoxy]benzyl]-1-methylpyrazole

cizolirtine *N*,*N*-diméthyl-2-[(*RS*)-(1-méthyl-1*H*-pyrazol-5-yl)phénylméthoxy]éthanamine

cizolirtina (±)-5-[α-[2-(dimetilamino)etoxi]bencil]-1-metilpirazol

$C_{15}H_{21}N_3O$



and enantiomer
et l'énantiomère
y enantiómero

dalcotidinum

dalcotidine

1-ethyl-3-[3-[(α-piperidino-*m*-tolyl)oxy]propyl]urea

dalcotidine

1-éthyl-3-[3-[3-[(pipéridin-1-yl)méthyl]phénoxy]propyl]urée

dalcotidina

1-etil-3-[3-[(α-piperidino-*m*-tolil)oxi]propil]urea

$C_{18}H_{29}N_3O_2$



daniplestimum

daniplestim

14-L-alanine-18-L-isoleucine-25-L-histidine-29-L-arginine-32-L-asparagine-37-L-proline-42-L-serine-45-L-methionine-51-L-arginine-55-L-threonine-59-L-leucine-62-L-valine-67-L-histidine-69-L-glutamic acid-73-glycine-76-L-alanine-79-L-arginine-82-L-glutamine-87-L-serine-93-L-serine-98-L-isoleucine-101-L-alanine-105-L-glutamine-109-L-glutamic acid-116-L-valine-120-L-glutamine-123-L-glutamic acid-14-125-interleukin 3 (human clone D11 reduced)

daniplestim

[14-L-alanine-18-L-isoleucine-25-L-histidine-29-L-arginine-32-L-asparagine-37-L-proline-42-L-sérine-45-L-méthionine-51-L-arginine-55-L-thréonine-59-L-leucine-62-L-valine-67-L-histidine-69-acide L-glutamique-73-glycine-76-L-alanine-79-L-arginine-82-L-glutamine-87-L-sérine-93-L-sérine-98-L-isoleucine-101-L-alanine-105-L-glutamine-109-acide L-glutamique-116-L-valine-120-L-glutamine-123-acide L-glutamique]-14-125-interleukin 3 (clone humain D11 précurseur de la partie protéique réduite)

daniplestim

[14-L-alanina-18-L-isoleucina-25-L-histidina-29-L-arginina-32-L-asparagina-37-L-prolina-42-L-serina-45-L-metionina-51-L-arginina-55-L-treonina-59-L-leucine-62-L-valina-67-L-histidina-69-ácido L-glutámico-73-glicina-76-L-alanina-79-L-arginina-82-L-glutamina-87-L-serina-93-L-serina-98-L-isoleucina-101-L-alanina-105-L-glutamina-109-ácido L-glutámico-116-L-valina-120-L-glutamina-123-ácido L-glutámico]-14-125-interleuquina 3 (clon humano D11 precursor de la fracción proteica reducida)

$C_{564}H_{909}N_{161}O_{166}S_5$



dexefaroxanum

dexefaroxan

(+)-(*R*)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline

dexéfaroxan

(+)-2-[(2*R*)-2-éthyl-2,3-dihydrobenzofuran-2-yl]-4,5-dihydro-1*H*-imidazole

dexefaroxán

(+)-(*R*)-2-(2-etil-2,3-dihidro-2-benzofuranil)-2-imidazolina

$C_{13}H_{16}N_2O$



elacridarum

elacridar — 4'-[2-(3,4-dihydro-6,7-dimethoxy-2(1*H*)-isoquinolyl)ethyl]-5-methoxy-9-oxo-4-acridancarboxanilide

élacridar — *N*-[4-[2-(6,7-diméthoxy-3,4-dihydroisoquinoléin-2(1*H*)-yl)éthyl]phényl]-5-méthoxy-9-oxo-9,10-dihydroacridine-4-carboxamide

elacridar — 4'-[2-(3,4-dihidro-6,7-dimetoxi-2(1*H*)-isoquinolil)etil]-5-metoxi-9-oxo-4-acridancarboxanilida

$C_{34}H_{33}N_3O_5$



eldacimibum

eldacimibe — cyclic isopropylidene [(3,5-di-*tert*-butyl-4-hydroxyanilino)[hexyl=(*p*-neopentylbenzyl)amino]methylene]malonate

eldacimibe — 5-[[[3,5-bis(1,1-diméthyléthyl)-4-hydroxyphényl]amino][[4-(2,2-diméthyl=propyl)benzyl]hexylamino]méthylène]-2,2-diméthyl-1,3-dioxane-4,6-dione

eldacimiba — [(3,5-di-*terc*-butil-4-hidroxianilino)[hexil(*p*-neopentilbencil)amino]=metileno]malonato cíclico de isopropilideno

$C_{39}H_{58}N_2O_5$



eperezolidum

eperezolid — *N*-[[(*S*)-3-[3-fluoro-4-(4-glycoloyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

épérézolide — *N*-[[(5*S*)-3-[3-fluoro-4-[4-(2-hydroxyacétyl)pipérazin-1-yl]phényl]-2-oxooxazolidin-5-yl]méthyl]acétamide

eperezolida — *N*-[[(*S*)-3-[3-fluoro-4-(4-glicoloil-1-piperazinil)fenil]-2-oxo-5-oxazolidinil]metil]acetamida

$C_{18}H_{23}FN_4O_5$



esatenololum

esatenolol — 2-[*p*-[(2*S*)-2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide

ésaténolol — 2-[4-[(2*S*)-2-hydroxy-3-[(1-méthyléthyl)amino]propoxy]phényl]acétamide

esatenolol — 2-[*p*-[(2*S*)-2-hidroxi-3-(isopropilamino)propoxi]fenil]acetamida

$C_{14}H_{22}N_2O_3$



faralimomabum

faralimomab — immunoglobulin G 1 (mouse monoclonal 64G12 γ1-chain anti-human interferon receptor), disulfide with mouse monoclonal 64G12 light chain, dimer

faralimomab — immunoglobuline G 1 (chaîne γ1 de l'anticorps monoclonal de souris (64G12) dirigé contre le récepteur humain des interférons de type I), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris 64G12

faralimomab — inmunoglobulina G 1 (cadena γ1 del anticuerpo monoclonal de ratón (64G12) dirigido contra el receptor humano de los interferones de tipo I), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón 64G12

gacyclidinum

gacyclidine	1-[*cis*-2-methyl-1-(2-thienyl)cyclohexyl]piperidine
gacyclidine	1-[(1*RS*,2*SR*)-2-méthyl-1-(thiophén-2-yl)cyclohexyl]pipéridine
gaciclidina	1-[*cis*-2-metil-1-(2-tienil)ciclohexil]piperidina
	$C_{16}H_{25}NS$



and enantiomer
et l'énantiomère
y enantiómero

ganaxolonum

ganaxolone	3α-hydroxy-3-methyl-5α-pregnan-20-one
ganaxolone	3α-hydroxy-3-méthyl-5α-prégnan-20-one
ganaxolona	3α-hidroxi-3-metil-5α-pregnan-20-ona
	$C_{22}H_{36}O_2$



hemoglobinum crosfumarilum

hemoglobin crosfumaril	hemoglobin A_0 (human $\alpha_2\beta_2$ tetrameric subunit), α-chain 99,99'-diamide with fumaric acid
hémoglobine crosfumaril	99,99'-diamide de la chaîne α de l'hémoglobine A_0 (sous-unité tétramérique $\alpha_2\beta_2$ humaine) avec l'acide fumarique
hemoglobina crosfumarilo	99,99'-diamida de la cadena α de la hemoglobina A_0 (subunidad tetramérica $\alpha_2\beta_2$ humana), con el ácido fumárico



indisetronum

indisetron

N-(3,9-dimethyl-*endo*-3,9-diazabicyclo[3 3.1]non-7-yl)-1*H*-indazole-3-carboxamide

indisétron

N-[(1*R*,5*S*,7*s*)-3,9-diméthyl-3,9-diazabicyclo[3.3.1]non-7-yl]-1*H*-indazole-3-carboxamide

indisetrón

N-(3,9-dimetil-*endo*-3,9-diazabiciclo[3.3.1]non-7-il)-1*H*-indazol-3-carboxamida

$C_{17}H_{23}N_5O$



insulinum aspartum

insulin aspart

28^B-L-aspartic acid-insulin (human)

insuline asparte

[28^B-acide L-aspartique]insuline humaine

insulina asparta

28^B-L-ácido aspártico-insulina(humana)

$C_{256}H_{381}N_{65}O_{79}S_6$



insulinum glarginum

insulin glargine

21^A-glycine-30^Ba-L-arginine-30^Bb-L-arginineinsulin (human)

insuline glargine

[21^A-glycine]$30a^B$-L-arginine-$30b^B$-L-arginine-insuline humaine

insulina glargina

21^A-glicina-30^Ba-L-arginina-30^Bb-L-argininainsulina (humana)

$C_{267}H_{404}N_{72}O_{78}S_6$



iometopanum (^{123}I)

iometopane (^{123}I) methyl 3β-(*p*-[^{123}I]iodophenyl)-1αH,5αH-tropane-2β-carboxylate

iométopane (^{123}I) (1*R*,2*S*,3*S*,5*S*)-3-(4-[^{123}I]iodophényl)-8-méthyl-8-azabicyclo[3 2 1]octane-2-carboxylate de méthyle

iometopano (^{123}I) 3β-(*p*-[^{123}I]iodofenil)-1αH,5αH-tropano-2β-carboxilato de metilo

$C_{16}H_{20}{}^{123}INO_2$



israpafantum

israpafant (±)-4-(*o*-chlorophenyl)-2-(*p*-isobutylphenethyl)-6,9-dimethyl-6*H*-thieno[3,2-*f*]-*s*-triazolo[4,3-*a*][1.4]diazepine

israpafant (6*RS*)-4-(2-chlorophényl)-6,9-diméthyl-2-[2-[4-(2-méthylpropyl)phényl]éthyl]-6*H*-thiéno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazépine

israpafant (±)-4-(*o*-chlorofenil)-2-(*p*-isobutilfenetil)-6,9-dimetil-6*H*-tieno[3,2-*f*]-*s*-triazolo[4,3-*a*][1,4]diazepina

$C_{28}H_{29}ClN_4S$



and enantiomer
et énantiomère
y enantiómero

keliximabum

keliximab immunoglobulin G 1 (human-Macaca monoclonal CE9.1 γ1-chain anti-human antigen CD 4), disulfide with human-Macaca monoclonal CE9 1 κ-chain, dimer

kéliximab immunoglobuline G 1 (chaîne γ1 de l'anticorps monoclonal chimérique homme-macaque CE9 1 dirigé contre l'antigène CD 4 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal chimérique homme-macaque CE9.1

keliximab inmunoglobulina G 1 (cadena γ1 del anticuerpo monoclonal químérico hombre-macaco CE9.1 dirigido contra el antígeno CD4 humano), dímero del disufuro con la cadena κ del anticuerpo monoclonal dimérico hombre-macaco CE9.1

lanoteplasum

lanoteplase

N-[*N* ^{2}-(*N*-glycyl-L-alanyl)-L-arginyl]-117-L-glutamine-245-L-methionine-(1-5)-(87-527)-plasminogen activator (human tissue-type protein moiety)

lanotéplase

N-[*N*^{2}-(*N*-glycyl-L-alanyl)-L-arginyl]-[117-L-glutamine-245-L-méthionine]- (1-5)-(87-527)- activateur du plasminogène (type tissulaire humain, partie protéique)

lanoteplasa

N-[*N* ^{2}-(*N*-glicil-L-alanil)-L-arginil]-[117-L-glutamina-245-L-metionina]-(1-5)-(87-527)-activador del plasminógeno (tipo tisular humano, fracción proteíca)

$C_{2194}H_{3323}N_{633}O_{666}S_{29}$



lasinavirum

lasinavir

tert-butyl [(α*S*)-α-[(1*S*,3*R*)-1-hydroxy-3-[[(1*S*)-1-[(2-methoxyethyl)carbamoyl]-2-methylpropyl]carbamoyl]-4-(2,3,4-trimethoxyphenyl)butyl]phenethyl]= carbamate

lasinavir

[(1*S*,2*S*,4*R*)-1-benzyl-2-hydroxy-5-[[(1*S*)-1-[(2-méthoxyéthyl)carbamoyl]-2-méthylpropyl]amino]-5-oxo-4-(2,3,4-triméthoxybenzyl)pentyl]carbamate de 1,1-diméthyléthyle

lasinavir

[(α*S*)-α-[(1*S*,3*R*)-1-hidroxi-3-[[(1*S*)-1-[(2-metoxietil)-carbamoil]-2-metilpropil]carbamoil]-4-(2,3,4-trimetoxifenil)butil]fenetil]carbamato de *terc*-butilo

$C_{35}H_{53}N_3O_9$



Iedoxantronum

Iedoxantrone — 5-[(2-aminoethyl)amino]-2-[2-(diethylamino)ethyl]-2*H*-[1]benzothiopyrano=[4,3,2-*cd*]indazol-8-ol

Iedoxantrone — 5-[(2-aminoéthyl)amino]-2-[2-(diéthylamino)éthyl]-2*H*-[1]benzothiopyrano=4,3,2-*cd*]indazol-8-ol

Iedoxantrona — 5-[(2-aminoetil)amino]-2-[2-(dietilamino)etil]-2*H*-[1]benzotiopirano=[4,3,2-*cd*]indazol-8-ol

$C_{21}H_{27}N_5OS$



linezolidum

linezolid — *N*-[[(*S*)-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide

linézolide — *N*-[[(5*S*)-3-[3-fluoro-4-(morpholin-4-yl)phényl]-2-oxooxazolidin-5-yl]méthyl]acétamide

linezolid — *N*-[[(*S*)-3-(3-fluoro-4-morfolinofenil)-2-oxo-5-oxazolidinil]metil]acetamida

$C_{16}H_{20}FN_3O_4$



lintuzumabum

lintuzumab — immunoglobulin G 1 (human-mouse monoclonal HuM195 γ1-chain anti-human antigen CD 33), disulfide with human monoclonal HuM195 κ-chain, dimer

lintuzumab — immunoglobuline G 1 (chaîne légère γ1 de l'anticorps monoclonal de souris humanisé HuM195 dirigé contre l'antigène CD 33 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal humain HuM195

lintuzumab — inmunoglobulina G 1 (cadena ligera γ1 del anticuerpo monoclonal de ratón humanizado HuM195 dirigido contra el antígeno CD 33 humano), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humano Hu195

metesindum

metesind — 4-[[α-[(2-aminobenz[*cd*]indol-6-yl)methylamino]-*p*-tolyl]sulfonyl]morpholine

métésind — 4-[[4-[[(2-aminobenzo[*cd*]indol-6-yl)(méthyl)amino]méthyl]phényl]= sulfonyl]morpholine

metesind — 4-[[α-[(2-aminobenz[*cd*]indol-6-il)metilamino]-*p*-tolil]sulfonil]morfolina

$C_{23}H_{24}N_4O_3S$



milfasartanum

milfasartan — methyl 2-[[4-butyl-2-methyl-6-oxo-5-[*p*-(*o*-1*H*-tetrazol-5-ylphenyl)benzyl]-1(6*H*)-pyrimidinyl]methyl]-3-thiophenecarboxylate

milfasartan — 2-[[4-butyl-2-méthyl-6-oxo-5-[4-[2-(1*H*-tétrazol-5-yl)phényl]bénzyl]pyrimidin-1(6*H*)-yl]méthyl]thiophène-3-carboxylate de méthyle

milfasartán — 2-[[4-butil-2-metil-6-oxo-5-[*p*-(*o*-1*H*-tetrazol-5-ilfenil)bencil]-1(6*H*)-pirimidinil]metil]-3-tiofenocarboxilato de metilo

$C_{30}H_{30}N_6O_3S$



minalrestatum

minalrestat — (±)-2-(4-bromo-2-fluorobenzyl)-6-fluorospiro[isoquinoline-4(1*H*),3'-pyrrolidine]-1,2',3,5'(2*H*)-tetrone

minalrestat — (3'*RS*)-2-(4-bromo-2-fluorobenzyl)-6-fluorospiro[isoquinoléine-4(1*H*),3'-pyrrolidine]-1,2',3,5'(2*H*)-tétrone

minalrestat — (±)-2-(4-bromo-2-fluorobencil)-6-fluoroespiro[isoquinolina-4(1*H*),3'-pirrolidin]-1,2',3,5'(2*H*)-tetrona

$C_{19}H_{11}BrF_2N_2O_4$



and enantiomer
et énantiomère
y enantiómero

nagrestipenum

nagrestipen — 26-L-alaninelymphokine MiP 1α (human clone pAT464 macrophage inflammatory)

nagrestipen — [26-L-alanine]lymphokine MiP 1α (clone pAT464 de macrophage inflammatoire humain)

nagrestipen — [26-L-alanina]linfoquina MiP 1α (clon pAT464 de macrófago inflamatorio humano)

$C_{338}H_{516}N_{88}O_{108}S_4$



nelfinavirum

nelfinavir — (3*S*,4a*S*,8a*S*)-*N*-*tert*-butyl-2-[(2*R*,3*R*)-3-(3,2-cresotamido)-2-hydroxy-4-(phenylthio)butyl]decahydro-3-isoquinolinecarboxamide

nelfinavir — (3*S*,4a*S*,8a*S*)-*N*-(1,1-diméthyléthyl)-2-[(2*R*,3*R*)-2-hydroxy-3-[(3-hydroxy-2-méthylbenzoyl)amino]-4-(phénylsulfanyl)butyl]décahydroisoquinoléine-3-carboxamide

nelfinavir — (3*S*,4a*S*,8a*S*)-*N*-*terc*-butil-2-[(2*R*,3*R*)-3-(3,2-cresotamido)-2-hidroxi-4-feniltio)butil]decahidro-3-isoquinolinacarboxamida

$C_{32}H_{45}N_3O_4S$



nerelimomabum

nerelimomab — immunoglobulin G 1 (mouse monoclonal BAYX1351 γ1-chain anti-human tumor necrosis factor α), disulfide with mouse monoclonal BAYX1351 light chain, dimer

nérélimomab — immunoglobuline G 1 (chaîne γ1 de l'anticorps monoclonal de souris BAYX1351 dirigé contre le facteur de nécrose tumorale α humain), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris BAYX1351

nerelimomab — inmunoglobulina G 1 (cadena ligera mouse monoclonal BAYX1351 γ1-chain anti-human tumor necrosis factor α), disulfide with mouse monoclonal BAYX1351 light chain, dimer

omiloxetinum

omiloxetine — 4'-fluoro-2-[*trans*-4-(*p*-fluorophenyl)-3-[[3,4-(methylenedioxy)= phenoxy]methyl]piperidino]acetophenone

omiloxétine — 2-[(3*RS*,4*SR*)-3-[(1,3-benzodioxol-5-yloxy)méthyl]-4-(4-fluorophényl)= pipéridin-1-yl]-1-(4-fluorophényl)éthanone

omiloxetino — 4'-fluoro-2-[*trans*-4-(*p*-fluorofenil)-3-[[3,4-(metilenodioxi)= fenoxi]metil]piperidino]acetofenona

$C_{27}H_{25}F_2NO_4$



and enantiomer
et l'énantiomère
y enantiómero

opratonii iodidum

opratonium iodide — trimethyl[3-(undecenamido)propyl]ammonium iodide

iodure d'opratonium — iodure de *N,N,N*-triméthyl-3-(undéc-10-énoylamino)propan-1-aminium

ioduro de opratonio — ioduro de trimetil[3-(undecenamido)propil]amonio

$C_{17}H_{35}IN_2O$



oprelvekinum

oprelvekin — 2-178-interleukin 11 (human clone pXM/IL-11)

oprelvékine — 2-178-interleukine 11 (clone humain pXM/IL-11)

oprelvekina — 2-178-interleuquina 11 (clon humano pXM/IL-11)

$C_{854}H_{1411}N_{253}O_{235}S_2$

GPPPGPPRVS PDPRAELDST VLLTRSLLAD TRQLAAQLR
KFPADGDHNL DSLPTLAMSA GALGALQLPG VLTRLRADL
SYLRHVQWLR RAGGSSLKTL EPELGTLQAR LDRLLRRLQ
LMSRLALPQP PPDPPAPPLA PPSSAWGGIR AAHAILGGL
LTLDWAVRGL LLLKTRL

osutidinum

osutidine — (±)-*N*-[(*E*)-[(*p*,β-dihydroxyphenethyl)amino][[2-[[5-[(methylamino)=methyl]furfuryl]thio]ethyl]amino]methylene]methanesulfonamide

osutidine — (*E*)-1-[(2*RS*)-2-hydroxy-2-(4-hydroxyphényl)éthyl]-3-[2-[[[5-[(méthylamino)=méthyl]-2-furyl]méthyl]sulfanyl]éthyl]-2-(méthylsulfonyl)guanidine

osutidina — (±)-*N*-[(*E*)-[(*p*,β-dihidroxifenetil)amino][[2-[[5-[(metilamino)=metil]furfuril]tio]etil]amino]metileno]metanosulfonamida

$C_{19}H_{28}N_4O_5S_2$



and enantiomer
et l'énantiomère
y enantiómero

pelubiprofenum

pelubiprofen (±)-*p*-[[(*E*)-2-oxocyclohexylidene]methyl]hydratropic acid

pélubiprofène acide (2*RS*)-2-[4-[(*E*)-(2-oxocyclohexylidène)méthyl]phényl]propanoïque

pelubiprofeno ácido(±)-*p*-[[(*E*)-2-oxociclohexilíden]metil]hidratrópico

$C_{16}H_{18}O_3$



and enantiomer
et énantiomère
y enantiómero

pumaprazolum

pumaprazole methyl 2-[[(2,3-dimethylimidazo[1,2-*a*]pyridin-8-yl)amino]methyl]-3-methylcarbanilate

pumaprazole 2-[[(2,3-diméthylimidazo[1,2-*a*]pyridin-8-yl)amino]méthyl]-3-méthylphényl]carbamate de méthyle

pumaprazol 2-[[(2,3-dimetilimidazo[1,2-a]piridin-8-il)amino]metil]-3-metilcarbanilato de metilo

$C_{19}H_{22}N_4O_2$



quilostigminum

quilostigmine (3a*S*,8a*R*)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-*b*]indol-5-yl 3,4-dihydro-2(1*H*)-isoquinolinecarboxylate

quilostigmine 3,4-dihydroisoquinoléine-2(1*H*)-carboxylate de (3a*S*,8a*R*)-1,3a,8-triméthyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-*b*]indol-5-yle

quilostigmina 3,4-dihidro-2(1*H*)-isoquinolinacarboxilato de (3a*S*,8a*R*)-1,2,3,3a,8,8a-hexahidro-1,3a,8-trimetilpirrolo[2,3-*b*]indol-5-ilo

$C_{23}H_{27}N_3O_2$



retigabinum

retigabine — ethyl 2-amino-4-[(*p*-fluorobenzyl)amino]carbanilate

rétigabine — [2-amino-4-[(4-fluorobenzyl)amino]phényl]carbamate d'éthyle

retigabina — 2-amino-4-[(*p*-fluorobencil)amino]carbanilato de etilo

$C_{18}H_{18}FN_3O_2$



sabcomelinum

sabcomeline — (*R*)-3-quinuclidineglyoxylonitrile (*Z*)-(*O*)-methyloxime

sabcoméline — (*Z*)-2-[(3*R*)-1-azabicyclo[2.2.2]oct-3-yl]-2-(méthoxyimino)acétonitrile

sabcomelina — (*R*)-3-quinuclidinaglioxilonitrilo (*Z*)-(*O*)-metiloxima

$C_{10}H_{15}N_3O$



scopinastum

scopinast — 7-[3-[4-[bis(*p*-fluorophenyl)hydroxymethyl]piperidino]propoxy]-6-methoxycoumarin

scopinast — 7-[3-[4-[bis(4-fluorophényl)hydroxyméthyl]pipéridin-1-yl]propoxy]-6-méthoxy-2*H*-chromén-2-one

escopinast — 7-[3-[4-[bis(*p*-fluorofenil)hidroximetil]piperidino]propoxi]-6-metoxicumarina

$C_{31}H_{31}F_2NO_5$



soretolidum

soretolide — 2,6-dimethyl-*N*-(5-methyl-3-isoxazolyl)benzamide

sorétolide — 2,6-diméthyl-*N*-(5-méthylisoxazol-3-yl)benzamide

soretolida — 2,6-dimetil-*N*-(5-metil-3-isoxazolil)benzamida

$C_{13}H_{14}N_2O_2$



tasonerminum

tasonermin — 1-157-tumor necrosis factor alfa-1a (human)

tasonermine — 1-157-facteur de nécrose tumorale humain alfa-1a

tasonermina — 1-157-factor de necrosis tumoral alfa-1a (humano)

$C_{778}H_{1225}N_{215}O_{231}S_2$

VRSSSRTPSD KPVAHVVANP QAEGQLQWLN RRANALLAN
VELRDNQLVV PSEGLYLIYS QVLFKGQGCP STHVLLTHT
SRIAVSYQTK VNLLSAIKSP CQRETPEGAE AKPWYEPIY
GGVFQLEKGD RLSAEINRPD YLDFAESGQV YFGIIAL

technetium (^{99m}Tc) nofetumomabum merpentanum

technetium (^{99m}Tc) nofetumomab merpentan — immunoglobulin G 2b (mouse monoclonal NR-LU-10 Fab fragment anti-human tumor), disulfide with mouse monoclonal NR-LU-10 κ-chain, [*N,N'*-[(2-formylethyl)ethylene]bis[2-mercaptoacetamidato](4-)*N,N',S,S'*]oxo=[^{99m}Tc]technetate(1-) conjugate

technétium (^{99m}Tc) nofétumomab merpentan — immunoglobuline G 2b (fragment Fab de l'anticorps monoclonal de souris NR-LU-10 dirigé contre une tumeur humaine), disulfure avec la chaîne κ de l'anticorps monoclonal de souris NR-LU-10 conjuguée avec l'oxo-[[*N,N'*-[1-(3-oxopropyl)éthane-1,2-diyl]bis[2-sulfanylacétamidato]](4-)-*N,N',S,S'*]=[^{99m}Tc]technétate(1-)

tecnecio (^{99m}Tc) nofetumomab merpentán — inmunoglobulina G 2b (fragmento Fab del anticuerpo monoclonal de ratón NR-LU-10 dirigido contra un tumor humano), disulfuro con la cadena κ del anticuerpo monoclonal de ratón NR-LU-10 conjugado con el oxo-[[*N,N'*-[1-(3-oxopropil)etano-1,2-diil]bis[2-sulfanilacetamidato]](4-)-*N,N',S,S'*]=[^{99m}Tc]tecnetato(1-)

temiverinum

temiverine — 4-(diethylamino)-1,1-dimethyl-2-butynyl (±)-α-phenylcyclohexaneglycolate

témivérine — (2*RS*)-2-cyclohexyl-2-hydroxy-2-phénylacétate de 4-(diéthylamino)-1,1-diméthylbut-2-ynyle

temiverina — (±)-α-fenilciclohexanoglicolato de 4-(dietilamino)-1,1-dimetil-2-butinilo

$C_{24}H_{35}NO_3$



and enantiomer
et l'énantiomère
y enantiómero

ticolubantum

ticolubant — (*E*)-6-[[(2,6-dichlorophenyl)thio]methyl]-3-(phenethyloxy)-2-pyridineacrylic acid

ticolubant — acide (*E*)-3-[6-[[(2,6-dichlorophényl)sulfanyl]méthyl]-3-(2-phényléthoxy)-pyridin-2-yl]prop-2-énoique

ticolubant — ácido (*E*)-6-[[(2,6-diclorofenil)tio]metil]-3-(fenetiloxi)-2-piridinacrílico

$C_{23}H_{19}Cl_2NO_3S$



valspodarum

valspodar — cyclo[[(2*S*,4*R*,6*E*)-4-methyl-2-(methylamino)-3-oxo-6-octenoyl]-L-valyl-*N*-methylglycyl-*N*-methyl-L-leucyl-L-valyl-*N*-methyl-L-leucyl-L-alanyl-D-alanyl-*N*-methyl-L-leucyl-*N*-methyl-L-leucyl-*N*-methyl-L-valyl]

valspodar — cyclo[L-alanyl-D-alanyl-*N*-méthyl-L-leucyl-*N*-méthyl-L-leucyl-*N*-méthyl-L-valyl-[(2*S*,4*R*,6*E*)-4-méthyl-2-(méthylamino)-3-oxooct-6-énoyl]-L-valyl-*N*-méthylglycyl-*N*-méthyl-L-leucyl-L-valyl-*N*-méthyl-L-leucyl]

valspodar — ciclo[[(2*S*,4*R*,6*E*)-4-metil-2-(metilamino)-3-oxo-6-octenoil]-L-valil-*N*-metilglicil-*N*-metil-L-leucil-L-valil-*N*-metil-L-leucil-L-alanil-D-alanil-*N*-metil-L-leucil-*N*-metil-L-leucil-*N*-metil-L-valil]

$C_{63}H_{111}N_{11}O_{12}$



vedaclidinum

vedaclidine

védaclidine

vedaclidina

(*S*)-3-[4-(butylthio)-1,2,5-thiadiazol-3-yl]quinuclidine

(3*S*)-3-[4-(butylsulfanyl)-1,2,5-thiadiazol-3-yl]-1-azabicyclo[2.2.2]octane

(*S*)-3-[4-(butiltio)-1,2,5-tiadiazol-3-il]quinuclidina

$C_{13}H_{21}N_3S_2$



AMENDMENTS TO PREVIOUS LISTS

Recommended International Nonproprietary Names (Rec. INN): List 30
(WHO Drug Information, Vol. 4, No. 3, 1990)

p. 13	saruplasum saruplase	*replace the definition by the following:* prourokinase (enzyme-activating) (human clone pUK4/pUK18), non-glycosylated

Recommended International Nonproprietary Names (Rec. INN): List 33
(WHO Drug Information, Vol. 7, No. 3, 1993)

p. 6	nasaruplasum nasaruplase	*replace the definition by the following* prourokinase (enzyme-activating) (human clone pA3/pD2/pF1 protein moiety), glycosylated



Recommended International Nonproprietary Names (Rec. INN): List 36
Dénominations communes internationales recommendées (DCI Rec.): Liste 36
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 36
(WHO Drug Information, Vol. 10, No. 3, 1996)

p.150	**levormeloxifenum**	
	levormeloxifene	*replace the chemical name by the following:* (-)-1-[2-[4-[(3*R*,4*R*)-7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy]=ethyl]pyrrolidine
	levormeloxifeno	*sustituyase el nombre quimico por lo siguiente:* (-)-1-[2-[4-[(3*R*,4*R*)-7-metoxi-2,2-dimetil-3-fenil-4-cromanil)fenoxi]=etil]pirrolidina

MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES

Dénominations communes internationales recommendées (DCI Rec.): Liste 30
(Informations pharmaceutiques OMS, Vol. 4, No.3, 1990)

p. 14	saruplasum saruplase	*remplacer la description par:* pro-urokinase (activateur d'enzyme) (fraction protéique issue du clone humain pUK4/pUK18), non-glycosylée

Dénominations communes internationales recommendées (DCI Rec.): Liste 33
(Informations pharmaceutiques OMS, Vol. 7, No.3, 1993)

p 6	nasaruplasum nasaruplase	*remplacer la description par:* pro-urokinase (activateur d'enzyme) (fraction protéique issue du clone humain pA3/pD2/pF1), glycosylée

Pour toutes modifications apportées aux **Dénominations communes internationales recommendées (DCI Rec.): Listes 34-37** voir page 181, séction *AMENDMENTS TO PREVIOUS LISTS.*

MODIFICACIONES A LAS LISTAS ANTERIORES

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 30
(Información Farmacéutica, OMS, Vol. 4, No. 3, 1990)

p. 13	saruplasum saruplasa	*sustituyase la descripción por la siguiente:* prouroquinasa (activador de enzima) (fracción proteica procedente del clon humano pUK4/pUK18), no glucosilada

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 33
(Información Farmacéutica, OMS, Vol. 7, No. 3, 1993)

p 6	nasaruplasum nasaruplasa	*sustituyase la descripción por la siguiente:* prouroquinasa (activador de enzima) (fracción proteica procedente del clon humano pA3/pD2/pF1), glucosilada

Para cualquier modificación de las **Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Listas 34-37** vease página 181, *sección AMENDMENTS TO PREVIOUS LISTS.*

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes impaires des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.